Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

详细信息	查看全文 | 推荐本文 |

• 作者：Ho-Young Yhim^a ; Na-Ri Lee^a ; ^b ; Eun-Kee Song^a ; ^b ; Chang-Yeol Yim^a ; ^b ; So Yeon Jeon^a ; Seunghwan Shin^c ; Jeong-A Kim^c ; Hee Sun Kim^d ; Eun Hae Cho^e ; Jae-Yong Kwak^a ; ^b ; ^{jykwak@jbnu.ac.kr}
• 关键词：Chronic myeloid leukemia ; Complete molecular response ; Imatinib mesylate ; Real-time quantitative polymerase chain reaction
• 刊名：Leukemia Research
• 出版年：2012
• 期刊代码：186_01452126
• 类别：med
• 出版时间：June, 2012
• 卷：36
• 期：6
• 页码：689-693
• 文件大小：270 K

摘要

The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5 months after discontinuation of IM. All 7 patients with high Sokal risk were relapsed. The probability of CMR persistence at 1-year was 28.6%. All relapsed patients were still responsive to IM. A high Sokal risk and delayed acquisition of CMR were associated with relapse. IM discontinuation in patients achieved CMR after treatment with front-line IM might be feasible. Further studies are warranted.